Rimonabant was the first clinically marketed cannabinoid (CB)1 receptor antagonist developed to treat obesity. Unfortunately. CB1 receptor antagonism produced adverse psychiatric events in patients. To determine whether this occurs pre-clinically. https://www.toyscyclers.shop/product-category/sorting/